$INO 👀 Old but goodie INO-4800 Selected for the U.S. Government's Operation Warp Speed - 94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 after two doses of INO-4800 in trial with 40 healthy volunteers in preliminary analyses - Through Week 8 INO-4800 regimen was deemed safe and well-tolerated with no serious adverse events; all reported adverse events were grade 1 in severity. ( AE Severity Grading Scale (NCI) one is described as Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated, The highest is grade 5 which is death) You cant ask for anything better...... - In preclinical animal challenge study, INO-4800 provided full protection against SARS-CoV-2 replication in the lungs in mice challenged with the virus - INOVIO to begin U.S. Phase 2/3 efficacy study this summer upon regulatory concurrence ir.inovio.com/news-releases/...
  • 4
4 Likes